Professor Nikola Bowden
Research Fellow
School of Medicine and Public Health (Medical Genetics)
- Email:nikola.bowden@newcastle.edu.au
- Phone:(02) 40420277
New life for tried-and-true cancer drugs
Awarding-winning molecular biologist Associate Professor Nikola Bowden is giving existing cancer drugs new life by combining them in unconventional ways with exciting results.
Over the years, the process of finding new cancer drug treatments has followed a strict pathway: the research reveals a biological discovery, which leads to a new drug discovery, drug development and testing through multiple stages of clinical trials.
The problem is, this entire process can take 15-20 years to complete. Which means that a patient who is diagnosed with aggressive cancer today will be unlikely to benefit from the most recent biological discoveries and subsequent treatments.
“We need to rethink our conventional approach to cancer research,” asserts Associate Professor Nikola Bowden, whose research focuses on repurposing existing cancer drugs. “We are wasting years of research and knowledge by shelving old drugs and trying to always find new ones.”
Instead of focusing on creating new drugs, Nikola and her team are looking at how existing drugs can be used in new ways. For cancer patients who need more immediate solutions, her work is having a meaningful impact.
“Using current drugs in new ways is called drug repurposing. We know so much about safety, dosing and side effects of the drugs we already use, it is ideal to also see if they have anti-cancer activity. We need to start using the drugs we already have to their full potential.”
Unlocking the mysteries of melanoma
Nikola spent many years as a lab-based scientist within a highly talented team. Her research helped shift the central dogma around the role of DNA repair in melanoma development. Nikola hypothesised that dysfunction in the pathway could provide an explanation for why the disease is largely resistant to chemotherapy.
“Chemotherapy usually works by attacking the DNA of a cancer cell and damaging it so badly that it dies. Normally, the DNA repair pathway in a cell will either fix the damage, as it does when we get sunburnt, or 'tell' a cell to die when the damage is extreme.
“But in melanoma this pathway is dysfunctional, so chemotherapy has little or no effect and the cancerous cells continue to accumulate damage and grow.”
Nikola’s breakthrough paper on nucleotide expression repair in melanoma, published in the journal Cancer Research in 2010, was the first to report on the relationship between DNA repair pathways and chemotherapy resistance in melanoma.
After presenting the findings to a patient consultation group, Nikola was challenged to start considering how the results could help improve treatments for patients. From that moment, her research career followed a new direction.
“I was immensely proud of our team’s success, but after meeting with local medical oncologist Dr Andre van der Westhuizen and several families touched by cancer, it became obvious that what was going to motivate us in the future was the chance to help cancer patients get the best possible treatment.”
New hope for complex cancer patients
Just over five years later, Nikola’s team is smaller, but their work is making a significant difference for cancer patients and their families.
First, based on their initial DNA repair research, the team successfully proved that certain drugs could be used to switch a patient's DNA repair back on and potentially trigger the immune system to help fight the cancerous cells.
“We found that using a combination of drugs in a staged approach would have the least impact on the patient. We are using the same drugs that have been around for 30-40 years, we simply used them for a new purpose."
Nikola and her team are now running clinical trials that are repurposing chemotherapy to treat melanoma patients who have no treatment options left.
“My team have repurposed old, ineffective cancer drugs into a new combination that is working well for patients with cancer that is resistant to all other treatments. It’s exciting to see the results of our lab work being developed into clinical trials and, best of all, to see patients responding to the drugs.”
Their goal is to find new ways to quickly and cost-effectively develop treatments that patients can take long-term, helping to increase their life expectancy. For these patients, time is critical. Using existing drugs in new ways, rather than waiting for new drugs to be developed, allows patients to access additional treatment options sooner.
“These patients usually have a very short prognosis, sometimes only weeks to live. We have treated 12 patients on our clinical trial in Newcastle and almost all of the patients are still alive. The longest survivor started on our trials two and a half years ago. It is the most amazing feeling to walk through the hospital knowing that you could walk past someone your research has kept alive.”
The clinical trial will soon be expanded to Queensland, and then Australia-wide. Nikola hopes the trials will give much-needed hope to complex cancer patients, prolonging their life and providing options where none have previously existed. The project will also prove that, sometimes, new isn’t always better.
“Our ultimate goal is that no cancer patient has to hear the words, ‘there is nothing more we can do for you’. Once we realise that the constant search for new drugs is actually a barrier to improving treatments, we will start to increase the success and speed of finding better treatments for cancer patients.”
New life for tried-and-true cancer drugs
Dr Nikola Bowden uses next-generation genetic profiling techniques to unlock the mysteries of melanoma.
Career Summary
Biography
A/Prof Bowden is co-Director of the University of Newcastle Centre for Drug Repurposing and Medicines Research and leads the DNA Repair Group. Her research has the overall aim of delivering personalised diagnosis and treatment to patients with cancer, with a more focused interest in investigating DNA repair and drug repurposing for melanoma and ovarian cancer.
Keywords
- Chemotherapy
- DNA repair
- Drug Repurposing
- Genetics
- Melanoma
- Ovarian cancer
- UV-light
Fields of Research
Code | Description | Percentage |
---|---|---|
321402 | Clinical pharmacology and therapeutics | 50 |
321104 | Cancer therapy (excl. chemotherapy and radiation therapy) | 50 |
Professional Experience
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
10/1/2018 - | Vanessa McGuigan HMRI Fellow in Ovarian Cancer | University of Newcastle - Faculty of Health and Medicine, School of Medicine and Public Health Australia |
1/1/2015 - 31/12/2017 | Cancer Institute NSW Career Development Fellow | University of Newcastle - Faculty of Health and Medicine |
1/10/2009 - 31/12/2014 | NHMRC Early Career Fellow | University of Newcastle - Faculty of Health and Medicine |
1/1/2009 - 1/10/2009 | Lecturer | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
1/1/2008 - 1/12/2008 | Postdoctoral Fellow - Gladys M. Brawn Memorial | University of Newcastle Australia |
1/1/2006 - 1/12/2007 | NBN Telethon Postdoctoral Fellow | University of Newcastle Hunter Medical Research Institute Australia |
Membership
Dates | Title | Organisation / Department |
---|---|---|
1/1/2012 - | Membership - NHMRC Post-Doctoral Reference Group | The NHMRC Postdoctoral Reference Group Australia |
1/1/2012 - | Membership - NHMRC Research Translation Faculty | NHMRC Research Translation Faculty Australia |
1/1/2010 - | Membership - Society for Melanoma Research | Society for Melanoma Research Australia |
1/1/2008 - | Membership - American Association of Cancer Research | American Association of Cancer Research United States |
1/1/2006 - | Membership - Australian Society of Medical Research | Australian Society of Medical Research Australia |
Professional appointment
Dates | Title | Organisation / Department |
---|---|---|
1/6/2015 - 31/12/2016 | Women in Science AUSTRALIA Executive committee | Women in Science AUSTRALIA Australia |
1/1/2014 - | Early-Mid Career Researcher Forum Committee Member | Australian Academy of Sciences Australia |
Awards
Award
Year | Award |
---|---|
2019 |
Australian Financial Review Emerging Leader in Higher Education Finalist Australian Financial Review |
2018 |
Cancer Institute NSW Research Fellow of the Year Finalist Cancer Institute NSW |
2016 |
Best Oral Presentation: Excellence in Translational Research HCRA Hunter Cancer Research Alliance |
2015 |
NSW Young Tall Poppy Science Award Australian Institute of Policy & Science (AIPS) |
2015 |
Best Oral Presentation: Pure Science Australian and New Zealand Gynaecological Oncology Group |
Recipient
Year | Award |
---|---|
2011 |
Young Alumni Award University of Newcastle |
Recognition
Year | Award |
---|---|
2012 |
Emerging Research Leaders Program University of Newcastle |
2007 |
INSIGHT Hunter Medical Research Institute |
Research Award
Year | Award |
---|---|
2007 |
Award for Research Excellence Hunter Medical Research Institute (HMRI) |
2006 |
PULSE Education Prize Hunter Medical Research Institute |
2006 |
Student Support Award to attend the International Congress on Human Genetics Society of Australasia (HGSA) |
2004 |
Student Travel Award International Society of Psychiatric Genetics |
2003 |
Student Travel Award Australasian Neuroscience Society |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (5 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2022 |
Navani V, Graves MC, Mandaliya H, Hong M, Van Der Westhuizen A, Martin J, Bowden NA, 'Melanoma: An immunotherapy journey from bench to bedside', Cancer Immunotherapies. Solid Tumors and Hematologic Malignancies, Springer, Cham, Switzerland 49-89 (2022) [B1]
|
||||||||||
2022 |
Navani V, Graves MC, Mandaliya H, Hong M, Van Der Westhuizen A, Martin J, Bowden NA, 'Melanoma: An immunotherapy journey from bench to bedside', Cancer Immunotherapies. Solid Tumors and Hematologic Malignancies, Springer, Cham, Switzerland 49-89 (2022) [B1]
|
Nova | |||||||||
2022 |
Buck J, Bowden N, Endersby R, 'Cancer therapies inducing DNA damage', Epigenetics and DNA Damage 205-225 (2022) [B1] The induction of DNA damage has been employed as an anticancer strategy for more than 100years, first starting with the use of radiation to treat stomach cancer followed by the fi... [more] The induction of DNA damage has been employed as an anticancer strategy for more than 100years, first starting with the use of radiation to treat stomach cancer followed by the first uses of DNA-damaging chemotherapy to treat childhood leukemia. Since those early pioneers, our understanding and application of radiotherapy, together with the discovery of many more anticancer chemotherapies, has revolutionized the clinical management of cancer. The broad mechanism of action for those earliest cancer treatments and the majority of therapies still used today are via the induction of DNA damage, resulting in cell death. However, therapy-induced DNA damage can sometimes be insufficient to induce cell death and can potentially be repaired via the DNA damage response and a variety of DNA repair pathways leading to treatment resistance. In normal and cancer cells, both the response to DNA damage and process of DNA repair are tightly regulated via gene expression and post-translational regulations such as phosphorylation. In addition, the DNA itself is in part controlled by the physical structure of chromatin, which is controlled by DNA methylation and various histone modifications. In this chapter, we discuss the various types of DNA damage-inducing therapies used in the clinical management of cancer. The types of therapies, their clinical use, and their mechanisms of action are highlighted, to provide a primer with which to understand the impacts of different treatments on both normal and cancer cells. This knowledge is essential to uncover new ways to improve cancer treatment, potentially by the addition of molecularly targeted drugs, such as epigenetic-modifying therapies, to existing upfront treatment regimens.
|
Nova | |||||||||
2022 |
Navani V, Graves MC, Mandaliya H, Hong M, Van Der Westhuizen A, Martin J, Bowden NA, 'Melanoma: An immunotherapy journey from bench to bedside', Cancer Immunotherapies. Solid Tumors and Hematologic Malignancies, Springer, Cham, Switzerland 49-89 (2022) [B1]
|
Nova | |||||||||
Show 2 more chapters |
Journal article (67 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2024 |
Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, Tooney PA, 'ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.', Oncotarget, 15 1-18 (2024) [C1]
|
Nova | |||||||||
2023 |
Maddison K, Bowden NA, Graves MC, Tooney PA, 'Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review', BMC Cancer, 23 (2023) [C1] Background: Glioblastoma, the most common primary malignant brain tumour in adults, is a highly vascular tumour characterised by abnormal angiogenesis. Additional mechanisms of tu... [more] Background: Glioblastoma, the most common primary malignant brain tumour in adults, is a highly vascular tumour characterised by abnormal angiogenesis. Additional mechanisms of tumour vascularisation have also been reported in glioblastoma, including the formation of tumour cell-derived vessels by vasculogenic mimicry (VM) or the transdifferentiation of tumour cells to endothelial cells. VM and endothelial transdifferentiation have frequently been reported as distinct processes, however, the use of both terms to describe a single process of vascularisation also occurs. Some overlapping characteristics have also been reported when identifying each process. We therefore aimed to determine the markers consistently attributed to VM and endothelial transdifferentiation in the glioblastoma literature. Methods: Ovid MEDLINE and Ovid Embase were searched for studies published between January 1999 and July 2021 that assessed VM or tumour to endothelial transdifferentiation in human glioblastoma. The online systematic review tool Covidence was used for screening and data extraction. Extracted data included type of tumour-derived vasculature reported, methods and techniques used, and markers investigated. Studies were grouped based on type of vasculature reported for further assessment. Results: One hundred and thirteen of the 419 unique records identified were included for analysis. VM was reported in 64/113 studies, while tumour to endothelial transdifferentiation was reported in 16/113 studies. The remaining studies used both terms to describe a single process, did not define the process that occurred, or concluded that neither VM nor endothelial transdifferentiation occurred. Absence of CD34 and/or CD31 in vascular structures was the most common indicator of VM, while expression of CD34 and/or CD31, in addition to various other endothelial, stem cell or tumour cell markers, indicated tumour to endothelial transdifferentiation. Conclusion: Cells derived from tumour to endothelial transdifferentiation express typical endothelial markers including CD34 and CD31, while tumour cells contributing to VM lack CD34 and CD31 expression. Additional tumour markers are required to identify transdifferentiation in glioblastoma tissue, and this process requires further characterisation.
|
Nova | |||||||||
2023 |
Maddison K, Faulkner S, Graves MC, Fay M, Bowden NA, Tooney PA, 'Vasculogenic Mimicry Occurs at Low Levels in Primary and Recurrent Glioblastoma', Cancers, 15 3922-3922 [C1]
|
Nova | |||||||||
2022 |
Harris MLL, Feyissa TRR, Bowden NAA, Gemzell-Danielsson K, Loxton D, 'Contraceptive use and contraceptive counselling interventions for women of reproductive age with cancer: a systematic review and meta-analysis', BMC MEDICINE, 20 (2022) [C1]
|
Nova | |||||||||
2022 |
Xie T, Dickson K-A, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ, 'Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival', CANCERS, 14 (2022) [C1]
|
Nova | |||||||||
2022 |
van der Westhuizen A, Lyle M, Graves MC, Zhu X, Wong JWH, Cornall K, et al., 'Repurposing azacitidine and carboplatin to prime immune checkpoint blockade-resistant melanoma for anti-PD-L1 re-challenge', Cancer Research Communications, 2 814-826 (2022) [C1]
|
Nova | |||||||||
2022 |
Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, Tooney PA, 'Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment', Cells, 11 (2022) [C1] Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arre... [more] Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arrest and repair treatment-induced DNA damage. We studied the expression of DDR, its relationship with standard treatment response and patient survival, and its activation after treatment. The transcriptomic profile of DDR pathways was characterised within a cohort of isocitrate dehydrogenase (IDH) wild-type glioblastoma from The Cancer Genome Atlas (TCGA) and 12 patient-derived glioblastoma cell lines. The relationship between DDR expression and patient survival and cell line response to temozolomide (TMZ) or radiation therapy (RT) was assessed. Finally, the expression of 84 DDR genes was examined in glioblastoma cells treated with TMZ and/or RT. Although distinct DDR cluster groups were apparent in the TCGA cohort and cell lines, no significant differences in OS and treatment response were observed. At the gene level, the high expression of ATP23, RAD51C and RPA3 independently associated with poor prognosis in glioblastoma patients. Finally, we observed a substantial upregulation of DDR genes after treatment with TMZ and/or RT, particularly in RTtreated glioblastoma cells, peaking within 24 h after treatment. Our results confirm the potential influence of DDR genes in patient outcome. The observation of DDR genes in response to TMZ and RT gives insight into the global response of DDR pathways after adjuvant treatment in glioblastoma, which may have utility in determining DDR targets for inhibition.
|
Nova | |||||||||
2022 |
Islam S, Wang S, Bowden N, Martin J, Head R, 'Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 88 64-74 (2022) [C1]
|
Nova | |||||||||
2022 |
Wong-Brown MW, van der Westhuizen A, Bowden NA, 'Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy', BMC CANCER, 22 (2022) [C1]
|
Nova | |||||||||
2021 |
Lozinski M, Bowden NA, Graves MC, Fay M, Tooney PA, 'DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets', CELLULAR ONCOLOGY, 44 961-981 (2021) [C1]
|
Nova | |||||||||
2021 |
Matthews BG, Bowden NA, Wong-Brown MW, 'Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer', CANCERS, 13 (2021) [C1]
|
Nova | |||||||||
2021 |
Maddison K, Graves MC, Bowden NA, Fay M, Vilain RE, Faulkner S, Tooney PA, 'Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma', Oncotarget, 12 2177-2187 (2021) [C1] Immunotherapies targeting tumour-infiltrating lymphocytes (TILs) that express the immune checkpoint molecule programmed cell death-1 (PD-1) have shown promise in preclinical gliob... [more] Immunotherapies targeting tumour-infiltrating lymphocytes (TILs) that express the immune checkpoint molecule programmed cell death-1 (PD-1) have shown promise in preclinical glioblastoma models but have had limited success in clinical trials. To assess when glioblastoma is most likely to benefit from immune checkpoint inhibitors we determined the density of TILs in primary and recurrent glioblastoma. Thirteen cases of matched primary and recurrent glioblastoma tissue were immunohistochemically labelled for CD3, CD8, CD4 and PD-1, and TIL density assessed. CD3+ TILs were observed in all cases, with the majority of both primary (69.2%) and recurrent (61.5%) tumours having low density of TILs present. CD8+ TILs were observed at higher densities than CD4+ TILs in both tumour groups. PD-1+ TILs were sparse and present in only 25% of primary and 50% of recurrent tumours. Quantitative analysis of TILs demonstrated significantly higher CD8+ TIL density at recurrence (p = 0.040). No difference was observed in CD3+ (p = 0.191), CD4+ (p = 0.607) and PD-1+ (p = 0.070) TIL density between primary and recurrent groups. This study shows that TILs are present at low densities in both primary and recurrent glioblastoma. Furthermore, PD-1+ TILs were frequently absent, which may provide evidence as to why anti-PD-1 immunotherapy trials have been largely unsuccessful in glioblastoma.
|
Nova | |||||||||
2021 |
Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, van der Westhuizen A, 'Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers', PHARMACOLOGY RESEARCH & PERSPECTIVES, 9 (2021) [C1]
|
Nova | |||||||||
2020 |
Wong-Brown MW, van der Westhuizen A, Bowden NA, 'Targeting DNA Repair in Ovarian Cancer Treatment Resistance', Clinical Oncology, 32 518-526 (2020) [C1] Most patients with advanced high-grade serous ovarian cancer (HGSOC) develop recurrent disease within 3 years and succumb to the disease within 5 years. Standard treatment for HGS... [more] Most patients with advanced high-grade serous ovarian cancer (HGSOC) develop recurrent disease within 3 years and succumb to the disease within 5 years. Standard treatment for HGSOC is cytoreductive surgery followed by a combination of platinum (carboplatin or cisplatin) and taxol (paclitaxel) chemotherapies. Although initial recurrences are usually platinum-sensitive, patients eventually develop resistance to platinum-based chemotherapy. Accordingly, one of the major problems in the treatment of HGSOC and disease recurrence is the development of chemotherapy resistance. One of the causes of chemoresistance may be redundancies in the repair pathways involved in the response to DNA damage caused by chemotherapy. These pathways may be acting in parallel, where if the repair pathway that is responsible for triggering cell death after platinum chemotherapy therapy is deficient, an alternative repair pathway compensates and drives cancer cells to repair the damage, leading to chemotherapy resistance. In addition, if the repair pathways are epigenetically inactivated by DNA methylation, cell death may not be triggered, resulting in accumulation of mutations and DNA damage. There are novel and existing therapies that can drive DNA repair pathways towards sensitivity to platinum chemotherapy or targeted therapy, thus enabling treatment-resistant ovarian cancer to overcome chemotherapy resistance.
|
Nova | |||||||||
2020 |
Navani V, Graves MC, Bowden NA, Van Der Westhuizen A, 'Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response', British Journal of Clinical Pharmacology, 86 1736-1752 (2020) [C1] Immune checkpoint blockade has transformed outcomes across solid organ tumours. Monoclonal antibodies targeting the negative inhibitory cytotoxic T lymphocyte-associated protein 4... [more] Immune checkpoint blockade has transformed outcomes across solid organ tumours. Monoclonal antibodies targeting the negative inhibitory cytotoxic T lymphocyte-associated protein 4 and programmed-death 1/programmed death-ligand 1 axis can lead to deep and durable responses across several tumour streams in the advanced setting. This immunotherapy approach is increasingly used earlier in the treatment paradigm. A rapidly evolving regulatory, reimbursement and drug development landscape has accompanied this novel class of immunotherapy. Unfortunately, only a small proportion of patients respond meaningfully to these agents. Here we review how the underlying tumoural genomic, histological and immunological characteristics interact within various patient phenotypes, leading to variations in response to checkpoint blockade. Concurrently, we outline the clinical trial and real-world evidence that allows for appropriate selection of agent, dose and schedule in solid organ malignancies. An exploration of current trends in basic and translational research in immune checkpoint blockade accompanies a commentary on future clinical directions for checkpoint blockade in oncology.
|
Nova | |||||||||
2019 |
Graves M, CelliMarchett G, van Zyl B, Tang D, Vilain RE, van der Westhuizen A, Bowden NA, 'Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles', FRONTIERS IN MEDICINE, 6 (2019) [C1]
|
Nova | |||||||||
2019 |
Budden T, Bowden NA, 'MC1R CpG island regulates MC1R expression and is methylated in a subset of melanoma tumours', PIGMENT CELL & MELANOMA RESEARCH, 32 320-325 (2019) [C1]
|
Nova | |||||||||
2019 |
Warren CFA, Wong-Brown MW, Bowden NA, 'BCL-2 family isoforms in apoptosis and cancer', Cell Death and Disease, 10 1-12 (2019) [C1]
|
Nova | |||||||||
2018 |
Van Zyl B, Tang D, Bowden NA, 'Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment', Endocrine-Related Cancer, 25 R303-R318 (2018) [C1] Ovarian cancer has poor survival rates due to a combination of diagnosis at advanced disease stages and disease recurrence as a result of platinum chemotherapy resistance. High-gr... [more] Ovarian cancer has poor survival rates due to a combination of diagnosis at advanced disease stages and disease recurrence as a result of platinum chemotherapy resistance. High-grade serous ovarian cancer (HGSOC), the most common ovarian cancer subtype, is conventionally treated with surgery and paclitaxel/carboplatin combination chemotherapy. Initial response rates are 60¿80%, but eventually the majority of patients become platinum-resistant with subsequent relapses. Extensive research on individual biomarkers of platinum resistance has revealed many potential targets for the development new treatments. While this is ongoing, there are also epigenetic, DNA repair, genome and immune changes characterised in platinum-resistant HGSOC that can be targeted with current therapies. This review discusses biomarkers of platinum chemotherapy resistance in ovarian cancer with a focus on biomarkers that are targetable with alternative treatment combinations to those currently used. After decades of research focused on elucidating the biological cause of platinum resistance, future research needs to focus on using this knowledge to overcome resistance for patients with ovarian cancer.
|
Nova | |||||||||
2018 |
Budden T, van der Westhuizen A, Bowden NA, 'Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma', BMC Cancer, 18 1-14 (2018) [C1]
|
Nova | |||||||||
2018 |
Scurry J, Van Zyl B, Gulliver D, Otton G, Kenneth J, Lombard J, et al., 'Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer', Gynecological Oncology, 151 306-310 (2018) [C1]
|
Nova | |||||||||
2016 |
Day T, Bowden N, Jaaback K, Otton G, Scurry J, 'Distinguishing erosive lichen planus from differentiated vulvar intraepithelial neoplasia', Journal of Lower Genital Tract Disease, 20 174-179 (2016) [C1] Erosive lichen planus and differentiated vulvar intraepithelial neoplasia may closely resemble each other histologically and require clinicopathological correlation to be distingu... [more] Erosive lichen planus and differentiated vulvar intraepithelial neoplasia may closely resemble each other histologically and require clinicopathological correlation to be distinguished. Objective Erosive lichen planus (LP) and differentiated vulvar intraepithelial neoplasia (dVIN) may display overlapping histopathologic features. Materials and Methods We searched the local pathology database for vulvar biopsies reported as dVIN or erosive vulvitis during 2011 to 2013 inclusive. After review of patient notes and slides, there were 5 cases with a clinical appearance and course consistent with erosive LP and histopathology showing epithelial regeneration. We then selected 5 cases of dVIN in which the clinical course and histopathology supported the diagnosis. We performed immunohistochemistry for p16 and p53 on all cases and did copy variant analysis on 1 case each of erosive LP and dVIN. Results Histopathology of the LP cases showed epithelial thinning, absent stratum corneum, lack of maturation, as well as nuclear changes of enlargement, pleomorphism, and hyperchromasia. Three LP cases (60%) showed a wild-type p53 pattern and 2 (40%) were confluent positive. Two dVIN cases (40%) showed full-thickness loss of differentiation. One case (20%) of dVIN was p53 negative, 2 (40%) were wild-type, 1 was confluent positive, and 1 showed dark suprabasilar staining. All cases were negative for p16. Compared with control, erosive LP epithelium showed a similar copy-number pattern, whereas the dVIN epithelium had many copy-number changes. Conclusions A small subset of clinically diagnosed vulvovaginal erosive LP will show on histopathology a regenerative erosive vulvitis with loss of epithelial maturation and nuclear changes, which requires clinicopathologic correlation to distinguish from dVIN.
|
Nova | |||||||||
2016 |
Murray HC, Maltby VE, Smith DW, Bowden NA, 'Nucleotide excision repair deficiency in melanoma in response to UVA', Experimental Hematology and Oncology, 5 (2016) [C1] Background: The causative link between UV exposure and melanoma development is well known, however the mechanistic relationship remains incompletely characterised. UVA and UVB com... [more] Background: The causative link between UV exposure and melanoma development is well known, however the mechanistic relationship remains incompletely characterised. UVA and UVB components of sunlight are implicated in melanomagenesis; however the majority of studies have focused on the effects of UVB and UVC light. Interestingly, melanoma tumour sequencing has revealed an overrepresentation of mutations signature of unrepaired UV-induced DNA damage. Repair of UVA-induced DNA damage is thought to occur primarily through the Nucleotide Excision Repair (NER) pathway, which recognises and repairs damage either coupled to transcription (Transcription Coupled Repair; TCR), or through global genome scanning (Global Genome Repair; GGR). Current literature suggests NER is deficient in melanoma, however the cause of this remains unknown; and whether reduced NER activity in response to UVA may be involved in melanoma development remains uncharacterised. In this study we aimed to determine if melanoma cells exhibit reduced levels of NER activity in response to UVA. Methods: Melanocyte and melanoma cell lines were UVA-irradiated, and DNA damage levels assessed by immunodetection of Cyclobutane Pyrimidine Dimer (CPD) and (6-4) Photoproduct [(6-4)PP] lesions. Expression of NER pathway components and p53 following UVA treatment was quantified by qPCR and western blot. Results: UVA did not induce detectable induction of (6-4)PP lesions, consistent with previous studies. Repair of CPDs induced by UVA was initiated at 4 h and complete within 48 h in normal melanocytes, whereas repair initiation was delayed to 24 h and >40 % of lesions remained in melanoma cell lines at 48 h. This was coupled with a delayed and reduced induction of GGR component XPC in melanoma cells, independent of p53. Conclusion: These findings support that NER activity is reduced in melanoma cells due to deficient GGR. Further investigation into the role of NER in UVA-induced melanomagenesis is warranted and may have implications for melanoma treatment.
|
Nova | |||||||||
2016 |
Bolton KA, Avery-Kiejda KA, Holliday EG, Attia J, Bowden NA, Scott RJ, 'A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer', ENDOCRINE CONNECTIONS, 5 115-122 (2016) [C1]
|
Nova | |||||||||
2016 |
Budden T, Davey RJ, Vilain RE, Ashton KA, Braye SG, Beveridge NJ, Bowden NA, 'Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair', ONCOTARGET, 7 60940-60953 (2016) [C1]
|
Nova | |||||||||
2016 |
Bolton KA, Holliday EG, Attia J, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer', BMC Research Notes, 9 (2016) [C1] Background: The estrogen-induced gene 121 (EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a genome-wide search fo... [more] Background: The estrogen-induced gene 121 (EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a genome-wide search for tandem repeats, we found that EIG121 contains a short tandem repeat (STR) in its upstream regulatory region which has the potential to alter gene expression. The presence of this STR has not previously been analysed in relation to breast or endometrial cancer risk. Results: In this study, the lengths of this STR were determined by PCR, fragment analysis and sequencing using DNA from 223 breast cancer patients, 204 endometrial cancer patients and 220 healthy controls to determine if they were associated with the risk of developing breast or endometrial cancer. We found this repeat to be highly variable with the number of copies of the AG motif ranging from 27 to 72 and having a bimodal distribution. No statistically significant association was identified between the length of this STR and the risk of developing breast or endometrial cancer or age at diagnosis. Conclusions: The STR in the upstream regulatory region of EIG121 is highly polymorphic, but is not associated with the risk of developing breast or endometrial cancer in the cohorts analysed here. While this polymorphic STR in the regulatory region of EIG121 appears to have no impact on the risk of developing breast or endometrial cancer, its association with disease recurrence or overall survival remains to be determined.
|
Nova | |||||||||
2016 |
Davey RJ, Westhuizen AVD, Bowden NA, 'Metastatic melanoma treatment: Combining old and new therapies', Critical Reviews in Oncology/Hematology, 98 242-253 (2016) [C1] Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a complex etiology. Until 2010, the treatment options for metastatic melanoma were very lim... [more] Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a complex etiology. Until 2010, the treatment options for metastatic melanoma were very limited. Largely ineffective dacarbazine, temozolamide or fotemustine were the only agents in use for 35 years. In recent years, the development of molecularly targeted inhibitors in parallel with the development of checkpoint inhibition immunotherapies has rapidly improved the outcomes for metastatic melanoma patients. Despite these new therapies showing initial promise; resistance and poor duration of response have limited their effectiveness as monotherapies. Here we provide an overview of the history of melanoma treatment, as well as the current treatments in development. We also discuss the future of melanoma treatment as we go beyond monotherapies to a combinatorial approach. Combining older therapies with the new molecular and immunotherapies will be the most promising way forward for treatment of metastatic melanoma.
|
Nova | |||||||||
2016 |
Hardy MC, Carter A, Bowden N, 'What do postdocs need to succeed? A survey of current standing and future directions for Australian researchers', Palgrave Communications, 2 (2016) [C1] When discussing the postdoctoral period in a researcher¿s life, a lack of career progression often boils down to ¿is it you, or is it me?¿ Is it a reduction in the quality of cand... [more] When discussing the postdoctoral period in a researcher¿s life, a lack of career progression often boils down to ¿is it you, or is it me?¿ Is it a reduction in the quality of candidates, or the fact that there are now too many candidates for a rapidly shrinking pool of jobs? Australia provides an ideal case study, as a large and decentralized country with a government mandate to build the STEMM (Science, Technology, Engineering, Mathematics and Medicine) workforce. The goal of the present study was 1) to provide a baseline for postdoctoral experiences and career aspirations in Australia, and 2) to identify gaps in postdoctoral training. When undertaking a capacity building programme it is important to know where efforts should be focused. To better understand the demographic and career progression of Australia¿s current cohort of postdoctoral researchers, a national survey was undertaken from 2014¿2015. More than 280 postdoctoral researchers from government, industry and academic institutions responded. Our results indicate that although postdoctoral researchers work more than the legal maximum of a 38-hour a week (on average) and have a long-term plan to stay in research, there is significant concern over the long-term viability of research careers due to job insecurity and a shortage of funding.
|
Nova | |||||||||
2015 |
Ashton KA, Scurry J, Tabrizi SN, Garland SM, Otton G, Bowden NA, 'The problem of late ovarian metastases from primary cervical adenocarcinoma.', Gynecologic oncology reports, 13 23-25 (2015) [C3]
|
||||||||||
2015 |
Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al., 'Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer', Breast Cancer Research and Treatment, 150 71-80 (2015) [C1] Triple-negative breast cancers¿(TNBC) lack expression of oestrogen, progesterone and HER2 receptors. The gene expression profiles of TNBCs are similar to those of breast tumours i... [more] Triple-negative breast cancers¿(TNBC) lack expression of oestrogen, progesterone and HER2 receptors. The gene expression profiles of TNBCs are similar to those of breast tumours in women with BRCA1 mutations. Reports to date indicate that up to 20¿% of TNBC patients harbour germline BRCA mutations; however, the prevalence of BRCA mutations in TNBC patients varies widely between countries and from study to study. We studied 774 women with triple-negative breast cancer, diagnosed on average at age 58.0¿years. Samples of genomic DNA were provided by the Australian Breast Cancer Tissue Bank (ABCTB) (439 patients) and by the Department of Genetics and Pathology of the Pomeranian Medical University (335 patients). The entire coding regions and the exon¿intron boundaries of BRCA1 and BRCA2 were amplified and sequenced by next-generation sequencing. We identified a BRCA1 or BRCA2 mutation in 74 of 774 (9.6¿%) triple-negative patients. The mutation prevalence was 9.3¿% in Australia and was 9.9¿% in Poland. In both countries, the mean age of diagnoses of BRCA1 mutation carriers was significantly lower than that of non-carriers, while the age of onset of BRCA2 mutation carriers was similar to that of non-carriers. In the Australian cohort, 59¿% of the mutation-positive patients did not have a family history of breast or ovarian cancer, and would not have qualified for genetic testing. The triple-negative phenotype should be added as a criterion to genetic screening guidelines.
|
Nova | |||||||||
2015 |
Bowden NA, Beveridge NJ, Ashton KA, Baines KJ, Scott RJ, 'Understanding xeroderma pigmentosum complementation groups using gene expression profiling after UV-light exposure', International Journal of Molecular Sciences, 16 15985-15996 (2015) [C1] Children with the recessive genetic disorder Xeroderma Pigmentosum (XP) have extreme sensitivity to UV-light, a 10,000-fold increase in skin cancers from age 2 and rarely live bey... [more] Children with the recessive genetic disorder Xeroderma Pigmentosum (XP) have extreme sensitivity to UV-light, a 10,000-fold increase in skin cancers from age 2 and rarely live beyond 30 years. There are seven genetic subgroups of XP, which are all resultant of pathogenic mutations in genes in the nucleotide excision repair (NER) pathway and a XP variant resultant of a mutation in translesion synthesis, POLH. The clinical symptoms and severity of the disease is varied across the subgroups, which does not correlate with the functional position of the affected protein in the NER pathway. The aim of this study was to further understand the biology of XP subgroups, particularly those that manifest with neurological symptoms. Whole genome gene expression profiling of fibroblasts from each XP complementation group was assessed before and after UV-light exposure. The biological pathways with altered gene expression after UV-light exposure were distinct for each subtype and contained oncogenic related functions such as perturbation of cell cycle, apoptosis, proliferation and differentiation. Patients from the subgroups XP-B and XP-F were the only subgroups to have transcripts associated with neuronal activity altered after UV-light exposure. This study will assist in furthering our understanding of the different subtypes of XP which will lead to better diagnosis, treatment and management of the disease.
|
Nova | |||||||||
2014 |
Evans T-J, Milne E, Anderson D, de Klerk NH, Jamieson SE, Talseth-Palmer BA, et al., 'Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures.', PLoS One, 9 e110255 (2014) [C1]
|
Nova | |||||||||
2014 |
Ashton KA, Scurry J, Ouveysi A, Ebbs J, Jaaback K, Bowden NA, 'Transformation of endometrioid carcinoma to carcinoma with trophoblastic differentiation: clinicopathological and whole genomic study.', Pathology, 46 351-353 (2014) [C3]
|
||||||||||
2014 |
Wong-Brown MW, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer', International Journal of Cancer, 134 301-305 (2014) [C1] Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor ... [more] Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor negativity. TNBCs share a similar gene expression profile to BRCA-mutated tumours, have been shown to carry a high proportion of BRCA mutations and have a more adverse prognosis compared to other types of breast tumours. PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. In our study, we sequenced the coding regions of PALB2 (including intron/exon boundaries) in genomic DNA from 347 patients diagnosed with TNBC to determine the prevalence of deleterious mutations in this population. Two novel truncating mutations (c.758dup and c.2390del) and one previously detected truncating mutation (c.3113+5G>C) were found. In addition, five variants predicted to be protein-affecting were also identified. Our study shows that the prevalence of PALB2 germline mutations in individuals with TNBC is ~1%, similar to the prevalence of PALB2 germline mutation of 1% in familial non-BRCA1/2 breast cancer cohorts. © 2013 UICC.
|
Nova | |||||||||
2014 |
Bowden NA, 'Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?', Cancer Letters, (2014) [C1] Platinum based therapy is one of the most effectively used chemotherapeutic treatments for cancer. The mechanism of action of platinum compounds is to damage DNA and drive cells i... [more] Platinum based therapy is one of the most effectively used chemotherapeutic treatments for cancer. The mechanism of action of platinum compounds is to damage DNA and drive cells into apoptosis. The most commonly used platinum containing agents are cis-diammine-dichloroplatinum (II)], more commonly known as cisplatin, its analogue carboplatin, and oxaliplatin. Cisplatin is used to treat a wide variety of tumours such as ovarian, testicular, head and neck and non-small cell lung cancers (NSCLCs). In addition, it forms the basis of most combined treatment regimes. Despite this, cisplatin and its analogues are extremely toxic and although some patients benefit substantially from treatment, a large proportion suffer the toxic side effects without any therapeutic benefit. Nucleotide excision repair (NER) is a versatile DNA repair system that recognises DNA damage induced by platinum based therapy. For many years the components of the NER pathway have been studied to determine mRNA and protein expression levels in response or resistance to cisplatin in many forms of cancer; particularly testicular, ovarian and NSCLCs. Despite the consistent finding that over or under expression of subsets of NER proteins and mRNA highly correlate with response to cisplatin, the translation of these findings into the clinical setting has not been forthcoming. This review summarises the results of previous investigations into NER in cisplatin response and clinical trials where the expression of NER proteins were compared to the response to platinum therapies in treatment. © 2014 Elsevier Ireland Ltd. All rights reserved.
|
Nova | |||||||||
2014 |
Wan C, Latter JL, Amirshahi A, Symonds I, Finnie J, Bowden N, et al., 'Progesterone Activates Multiple Innate Immune Pathways in Chlamydia trachomatis-Infected Endocervical Cells', American Journal of Reproductive Immunology, 71 165-177 (2014) [C1] Problem: Susceptibility to Chlamydia trachomatis infection is increased by oral contraceptives and modulated by sex hormones. We therefore sought to determine the effects of femal... [more] Problem: Susceptibility to Chlamydia trachomatis infection is increased by oral contraceptives and modulated by sex hormones. We therefore sought to determine the effects of female sex hormones on the innate immune response to C. trachomatis infection. Method of study: ECC-1 endometrial cells, pre-treated with oestradiol or progesterone, were infected with C. trachomatis and the host transcriptome analysed by Illumina Sentrix HumanRef-8 microarray. Primary endocervical epithelial cells, prepared at either the proliferative or secretory phase of the menstrual cycle, were infected with C. trachomatis and cytokine gene expression determined by quantitative RT-PCR analysis. Results: Chlamydia trachomatis yield from progesterone-primed ECC-1 cells was significantly reduced compared with oestradiol-treated cells. Genes upregulated in progesterone-treated and Chlamydia-infected cells only included multiple CC and CXC chemokines, IL-17C, IL-29, IL-32, TNF-a, DEFB4B, LCN2, S100A7-9, ITGAM, NOD2, JAK1, IL-6ST, type I and II interferon receptors, numerous interferon-stimulated genes and STAT6. CXCL10, CXCL11, CX3CL1 and IL-17C, which were also upregulated in infected secretory-stage primary cells, and there was a trend towards higher levels of immune mediators in infected secretory-phase compared with proliferative-phase cells. Conclusion: Progesterone treatment primes multiple innate immune pathways in hormone-responsive epithelial cells that could potentially increase resistance to chlamydial infection. © 2013 John Wiley & Sons Ltd.
|
Nova | |||||||||
2014 |
Cox MB, Bowden NA, Scott RJ, Lechner-Scott J, 'Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis', Multiple Sclerosis Journal, 20 489-491 (2014) [C1] Matrix metalloproteinase 9 (MMP9) is involved in multiple sclerosis (MS) aetiology. Previously, we identified differential gene expression of plasminogen activation cascade genes ... [more] Matrix metalloproteinase 9 (MMP9) is involved in multiple sclerosis (MS) aetiology. Previously, we identified differential gene expression of plasminogen activation cascade genes in MS patients. Based on our gene expression results, we wanted to identify whether polymorphisms in the genes associated with the plasminogen pathway could predict MS risk. We genotyped 1153 trio families, 727 MS cases and 604 healthy controls for 17 polymorphisms in MMP9, plasminogen activator urokinase (PLAU), PLAU receptor (PLAUR) and serpin peptidase inhibitor/clade 2/member B2 (SERPINB2) genes. No associations were found between the 17 polymorphisms and MS. Also, gene expression levels were analysed according to genotype: no associations were observed. In conclusion despite the consistent evidence for the role of MMP9 and the plasminogen activation cascade in MS, we found no associations between genotype nor gene expression. This suggested there are other potentially modifiable factors influencing gene expression in MS. © The Author(s) 2013.
|
Nova | |||||||||
2013 |
Cox MB, Bowden NA, Scott RJ, Lechner-Scott J, 'Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation', Multiple Sclerosis Journal, 19 1268-1274 (2013) [C1]
|
Nova | |||||||||
2013 |
Budden T, Bowden NA, 'The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 14 1132-1151 (2013) [C1]
|
||||||||||
2013 |
Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'STaRRRT: a table of short tandem repeats in regulatory regions of the human genome', BMC GENOMICS, 14 (2013) [C1]
|
Nova | |||||||||
2013 |
Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, et al., 'Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma', PLOS ONE, 8 (2013) [C1]
|
Nova | |||||||||
2012 |
Ashton KA, Scurry JP, Rutherford J, Otton GR, Scott R, Bowden NA, 'Nodular prurigo of the vulva', Pathology, 44 565-567 (2012) [C3]
|
||||||||||
2012 |
Young KMN, Scurry JP, Jaaback KS, Bowden NA, Scott R, 'Bilateral dysgerminoma associated with gonadoblastoma and sex-cord stromal tumour with annular tubules in a 28-year-old fertile woman with normal karyotype', Pathology, 44 257-260 (2012) [C3]
|
Nova | |||||||||
2012 |
Cox MB, Ban M, Bowden NA, Baker A, Scott R, Lechner-Scott J, 'Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis', Multiple Sclerosis Journal, 18 16-22 (2012) [C1]
|
Nova | |||||||||
2011 |
Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al., 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', BMC Cancer, 11 203-219 (2011) [C1]
|
Nova | |||||||||
2011 |
Wong-Brown M, Nordfors C, Mossman D, Pecenpetelovska G, Kiejda KA, Talseth-Palmer B, et al., 'BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer', Breast Cancer Research and Treatment, 127 853-859 (2011) [C1]
|
Nova | |||||||||
2010 |
Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Nucleotide excision repair gene expression after cisplatin treatment in melanoma', Cancer Research, 70 7918-7926 (2010) [C1]
|
Nova | |||||||||
2010 |
Li J, Wang W, Baines KJ, Bowden NA, Hansbro PM, Gibson PG, et al., 'IL-27/IFN-y induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages', Journal of Immunology, 185 4401-4409 (2010) [C1]
|
Nova | |||||||||
2010 |
Baines KJ, Simpson JL, Bowden NA, Scott R, Gibson PG, 'Differential gene expression and cytokine production from neutrophils in asthma phenotypes', European Respiratory Journal, 35 522-531 (2010) [C1]
|
Nova | |||||||||
2009 |
Talseth-Palmer B, Bowden NA, Meldrum C, Nicholl J, Thompson E, Friend K, et al., 'A 1q44 deletion, paternal UPD of chromosome 2 and a deletion due to a complex translocation detected in children with abnormal phenotypes using new SNP array technology', Cytogenetic and Genome Research, 124 94-101 (2009) [C1]
|
Nova | |||||||||
2008 |
Bowden NA, Scott R, Tooney PA, 'Altered gene expression in the superior temporal gyrus in schizophrenia', BMC Genomics, 9 1-12 (2008) [C1]
|
Nova | |||||||||
2008 |
Talseth-Palmer B, Bowden NA, Hill A, Meldrum C, Scott R, 'Whole genome amplification and its impact on CGH array profiles', BMC Research Notes, 1 108 (2008) [C1]
|
Nova | |||||||||
2008 |
Beveridge NJ, Tooney PA, Carroll AP, Gardiner EJ, Bowden NA, Scott R, et al., 'Dysregulation of miRNA 181b in the temporal cortex in schizophrenia', Human Molecular Genetics, 17 1156-1168 (2008) [C1]
|
Nova | |||||||||
2007 |
Bowden NA, Scott R, Tooney PA, 'Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia', Schizophrenia Research, 89 165-168 (2007) [C1]
|
||||||||||
2007 |
Bowden NA, Croft A, Scott R, 'Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease', Hereditary Cancer in Clinical Practice, 5 79-96 (2007) [C1]
|
||||||||||
2006 |
Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Altered gene expression in the amygdala in schizophrenia: Up-regulation of genes located in the cytomatrix active zone', Molecular and Cellular Neuroscience, 31 243-250 (2006) [C1]
|
||||||||||
2006 |
Bowden NA, Weidenhofer JC, Scott R, Schall U, Todd J, Michie PT, Tooney PA, 'Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia', Schizophrenia Research, 82 175-183 (2006) [C1]
|
Nova | |||||||||
2006 |
Bowden NA, Tooney PA, Scott R, 'Gene expression profiling of xeroderma pigmentosum', Hereditary Cancer in Clinical Practice, 4 103-110 (2006) [C1]
|
Nova | |||||||||
Show 64 more journal articles |
Conference (116 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2021 |
Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, Van Der Westhuizen A, 'Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers.', CANCER RESEARCH, PA, Philadelphia (2021)
|
|||||||
2020 |
Blackburn A, Motion A, Bowden N, Chen T, Martin J, 'Drug repurposing for coronavirus treatment a stimulus for an examination of drug development trials, regulation and financing', Canberra (2020)
|
|||||||
2020 |
Blackburn A, Motion A, Bowden N, Chen T, Martin J, 'Drug repurposing for cancer treatment an examination of drug development trials, regulation and financing.', Australia (2020)
|
|||||||
2014 |
Warren CFA, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'Association of BCL-2B expression with increased survival and response to stress in melanoma suggests a functional role for this previously uncharacterised isoform.', Keystone Symposia on Molecular and Cellular Biology, Sao Paulo, Brazil (2014) [E3]
|
|||||||
2014 | Bowden NA, 'Overcoming chemoresistance in melanoma and ovarian cancer.', Proceedings of the Inaugural EMBL Australia PhD Symposium, Sydney, NSW, Australia (2014) [E3] | |||||||
2014 |
Warren CFA, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'A functional role in cellular stress response and melanoma pathology for the previously uncharacterised isoform, Bcl-2B.', Proceedings of the Inaugural EMBL Australia PhD Symposium, Sydney, NSW, Australia (2014) [E3]
|
|||||||
2014 |
Budden T, Davey RJ, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'Repair of UVB-induced DNA damage is reduced in melanoma due to attenuated XPC and global genome repair.', Proceedings of the Inaugural EMBL Australia PhD Symposium, Sydney, NSW, Australia (2014) [E3]
|
|||||||
2014 | Bowden NA, 'How melanoma and melanocytes respond to UV-light and chemotherapy', Skin Cancer College of Australasia, Surfers Paradise, Qld, Australia (2014) [E3] | |||||||
2014 |
Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple diseases.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014) [E3]
|
|||||||
2014 |
Davey RJ, Budden T, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'REPAIR OF UVB-INDUCED DNA DAMAGE IS REDUCED IN MELANOMA DUE TO ATTENUATED XPC AND GLOBAL GENOME REPAIR', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014)
|
|||||||
2014 |
Budden T, Bowden NA, 'GLOBAL DEMETHYLATION CAN RESTORE XPC EXPRESSION AND OVERCOME PLATINUM THERAPY RESISTANCE IN MELANOMA IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
Davey RJ, Budden T, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'REPAIR OF UVB-INDUCED DNA DAMAGE IS REDUCED IN MELANOMA DUE TO ATTENUATED XPC AND GLOBAL GENOME REPAIR', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'A FUNCTIONAL ROLE IN MELANOMA PATHOLOGY AND CELLULAR RESPONSE TO STRESS FOR THE PREVIOUSLY UNCHARACTERISED ISOFORM, BCL2B', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
Murray HC, Maltby VE, Bowden NA, 'Nucleotide excision repair in response to UVA is deficient in melanoma.', Pigment Cell and Melanoma Research, Singapore (2014) [E3]
|
|||||||
2014 |
Budden T, Bowden NA, 'Melanoma exhibits defective nucleotide excision repair of UVB-induced DNA photoproducts', Pigment Cell and Melanoma Research, Singapore (2014) [E3]
|
|||||||
2014 |
Bolton KA, Holliday EG, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is a modifier of disease risk in endometrial cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
|
|||||||
2014 |
Davey RJ, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'XPC expression is associated with BRAFV600E and NRASQ61R mutations and poor survival in melanoma.', ASMR Satellite scientific meeting proceedings, Newcastle, NSW, Australia (2014) [E3]
|
|||||||
2014 | Murray HC, Maltby VE, Bowden NA, 'Nucleotide excision repair function in melanoma.', ASMR Satellite scientific meeting proceedings, Newcastle, NSW, Australia (2014) [E3] | |||||||
2014 |
Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'The expression of the previously uncharacterised isoform, Bcl-2B is associated with increased survival in melanoma.', ASMR Satellite scientific meeting proceedings, Newcastle, NSW, Australia (2014) [E3]
|
|||||||
2014 | Budden T, Bowden NA, 'Melanoma displays reduced nucleotide excision repair in response to UVB-induced DNA damage', ASMR Scientific Satellite Meeting Proceedings, Newcastle, NSW, Australia (2014) [E3] | |||||||
2014 |
Bolton KA, Holliday EG, McEvoy M, Attia J, Proietto A, Otton G, et al., 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen gene EIG121 is a potential modifier of endometrial cancer risk.', Asia-Pacific Journal of Clinical Oncology, Newcastle, NSW, Australia (2014) [E3]
|
|||||||
2014 | Bowden NA, 'Investigation of the nucleotide excision repair pathway for melanoma biomarkers', Cure Cancer Australia symposium proceedings, Sydney, NSW, Australia (2014) [E3] | |||||||
2013 |
Bolton KA, Ross J, Grice DM, Avery-Kiejda KA, Bowden NA, Holliday EG, Scott RJ, 'Role of Short Tandem Repeats in Disease and Evolutionary Mechanisms.', 34th Lorne Genome Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
|
|||||||
2013 |
Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden N, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in familial breast cancer.', Kathleen Cunningham Foundation Consortium for Research into Familial Aspects of Cancer 2013 Research and Practice Proceedings, Cairns, QLD, Australia. (2013) [E3]
|
|||||||
2013 |
Wong-Brown M, Avery-Kiejda K, Bowden N, Scott R, 'Prevalence of BRCA1 and BRCA2 germline mutations in triple-negative breast cancer', Programme, Newcastle (2013) [E3]
|
|||||||
2013 |
Bolton KA, Avery-Kiejda KA, Grice DM, Holliday EG, Bowden NA, Ross J, Scott RJ, 'STaRRRT: Our new resource for identifying candidates of genetic risk in breast and endometrial cancer.', Translational Cancer Research Conference Abstract booklet, Newcastle, Australia (2013) [E3]
|
|||||||
2012 |
Bolton KA, Ross J, Grice DM, Kiejda KA, Bowden NA, Holliday EG, Scott R, 'Potential role of short tandem repeats in disease processes', Abstracts. 6th Australian Health & Medical Research Congress, Adelaide, SA (2012) [E3]
|
|||||||
2012 |
Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Exploratory targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Programme. kConFab Familial Aspects of Cancer: Research & Practice 2012, Kingscliff, NSW (2012) [E3]
|
|||||||
2012 |
Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Cancer Research, San Antonio, Texas (2012) [E3]
|
|||||||
2011 |
Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
|
Nova | ||||||
2011 | Johansson P, Wei JS, Chen Q, Bowden NA, Badgett TC, Song YK, et al., 'A genomic portrait of tumor progression using next-generation sequencing', American Association for Cancer Research (AACR) 102nd Annual Meeting. Innovation and Collaboration: The Path to Progress Proceedings, Orlando, FL (2011) [E3] | |||||||
2010 |
Croft AJ, Kiejda KA, Bowden NA, Zhang X, Scott R, Hersey P, 'Expression profiling on apoptosis-related genes in cisplatin-treated human melanoma cell lines', 22nd Lorne Cancer Conference: Abstracts and Delegate Information, Lorne, Vic. (2010) [E3]
|
|||||||
2010 |
Wong-Brown M, Bowden NA, Kiejda KA, Scott R, 'BRIP1 and PALB2 mutation detection in Hunter-New England familial breast cancer cohort', 27th HUGO-IABCR Congress 2010. Genomics, Biology and Breast Cancer Treatment. Programme & Abstract Book, Biopolis, Singapore (2010) [E3]
|
|||||||
2010 |
Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
|
|||||||
2010 |
Ashton KA, Bowden NA, Kairupan CF, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Base excision repair and gene expression profiling in malignant melanoma', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
|
|||||||
2010 |
Wong-Brown M, Bowden NA, Forbes JF, Braye SG, Scott R, 'Microsatellite instability (I) in breast tumours', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
|
|||||||
2010 |
Ashton KA, Bowden NA, Vilain RE, Kairupan CF, Kiejda KA, Zhang XD, et al., 'Genetic variation of the base excision repair gene, MUTYH, and melanoma development', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
|
|||||||
2010 |
Bowden NA, Ashton KA, Kiejda KA, Vilain RE, Braye SG, Kairupan CF, et al., 'Nucleotide excision repair gene expression in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
|
|||||||
2010 |
Vilain RE, Ashton KA, Bowden NA, Braye SG, Ashman LK, Scott RJ, 'Clinicopathological and gene expression profiling of advanced melanoma harbouring KIT and common kinase mutations', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
|
|||||||
2009 |
Kiejda KA, Scurr LL, Wade MA, Jiang CC, Weir AJW, Bowden NA, et al., 'Cisplatin induces apoptosis independently of Noxa or PUMA in human melanoma cells', 21st Lorne Cancer Conference, Lorne, VIC (2009) [E3]
|
|||||||
2009 |
Cox MB, Bowden NA, Scott R, Lechner-Scott J, 'Gene expression profiling in multiple sclerosis', AMATA 2009, Katoomba, NSW (2009) [E3]
|
|||||||
2009 |
Evans T-J, Bowden NA, Talseth-Palmer B, Catchpoole D, Scott R, 'Copy number variation in childhood acute lmphoblastic leukaemia', AMATA 2009, Katoomba, NSW (2009) [E3]
|
|||||||
2009 |
Bowden NA, Ashton KA, Stibbard GJ, Cox MB, Baines KJ, Scott R, 'Predicting xeroderma pigmentosum complementation group by gene expression profiling', AMATA 2009, Katoomba, NSW (2009) [E3]
|
|||||||
2009 |
Kairupan CF, Bowden NA, Ashton KA, Zhang XD, Hersey P, Scott R, 'Gene expression profiling in malignant melanoma', AMATA 2009, Katoomba, NSW (2009) [E3]
|
|||||||
2008 |
Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', Proceedings of the Australian Health and Medical Research Congress 2008, Brisbane, QLD (2008) [E3]
|
|||||||
2008 |
Bowden NA, Baines KJ, Cox MB, Scott R, 'Altered gene expression in nucleotide excision repair deficient fibroblasts after UV-light exposure', AACR Meeting Abstracts, San Diego, CA (2008) [E3]
|
|||||||
2008 |
Bowden NA, Baines KJ, Cox MB, Scott R, 'Response to uv-light exposure in fibroblasts with differential nucleotide excision repair capacity', ASMR XVII NSW Scientific Meeting: Programme and Abstracts, Sydney, NSW (2008) [E3]
|
|||||||
2008 |
Bowden NA, Ashton KA, Baines KJ, Cox MB, Scott R, 'Altered gene expression after UV-light induced DNA damage', Conference on Translational Cancer Research: Abstracts, Newcastle, NSW (2008) [E3]
|
|||||||
2007 |
Baines KJ, Bowden NA, Scott R, Simpson JL, Gibson PG, 'Molecular analysis of neutrophils in asthma subtypes', Respirology (TSANZ Abstracts-Posters), Auckland (2007) [E3]
|
|||||||
2007 |
Cox M, Bowden NA, Moscato PA, Berretta RE, Scott R, 'Memetic algorithms as a new method to interpret gene expression profiles in multiple sclerosis', Multiple Sclerosis (Abstracts of the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 12th Annual Conference of Rehabilitation in Multiple Sclerosis), Prague, Czech Republic (2007) [E3]
|
|||||||
2007 |
Tooney PA, Scott R, Cairns MJ, Bowden NA, 'Altered gene expression in the superior temporial gyrus in schizophrenia', Schizophrenia Bulletin (Abstracts of the 11th International Congress on Schizophrenia Research), Colorado Springs, Colorado (2007) [E3]
|
|||||||
2006 |
Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Dysfunction of genes regulating membrane exocytosis in schizophrenia (Poster presentation)', Australian and New Zealand Journal of Psychiatry (Vol 40, noS2), Fremantle, Western Australia (2006) [E3]
|
|||||||
2005 |
Bowden NA, Weidenhofer JC, Scott R, Schall UA, Todd J, Michie PT, Tooney PA, 'Classification of schizophrenia using differential gene expression in peripheral blood lymphocytes', Human Genetics Society of Australasia, Newcastle (2005) [E3]
|
|||||||
2004 |
Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Altered Expression of Brain Related Genes in Lymphocytes in Schizophrenia', American Journal of Medical Genetics, Ireland (2004) [E3]
|
Nova | ||||||
2004 |
Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Gene Profiling in the Amygdala in Schizophrenia', American Journal of Medical Genetics, Ireland (2004) [E3]
|
|||||||
2004 |
Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Differental Gene Expression in Peripheral Blood Lymphocytes in Schizophrenia', Proceedings of the Australian Neuroscience Society, Melbourne (2004) [E3]
|
|||||||
2004 |
Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Altered Gene Expression Profiles in the Amygdala in Schizophrenia', Proceedings of the Australian Neuroscience Society, Melbourne (2004) [E3]
|
|||||||
2004 |
Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Distinct Gene Expression Profiles due to Age in Schizophrenia', Proceedings of the Australian Neuroscience Society, Melbourne (2004) [E3]
|
|||||||
Show 113 more conferences |
Other (6 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2023 |
van der Westhuizen A, Lyle M, Graves MC, Zhu X, Wong JWH, Cornall K, et al., 'Supplementary Figure 2 from Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade resistant Melanoma for Anti-PD-L1 Rechallenge', American Association for Cancer Research (AACR) (2023)
|
|||||||
2023 |
van der Westhuizen A, Lyle M, Graves MC, Zhu X, Wong JWH, Cornall K, et al., 'Supplementary Figure 1 from Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade resistant Melanoma for Anti-PD-L1 Rechallenge', American Association for Cancer Research (AACR) (2023)
|
|||||||
2023 |
van der Westhuizen A, Lyle M, Graves MC, Zhu X, Wong JWH, Cornall K, et al., 'Supplementary Figure 2 from Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade resistant Melanoma for Anti-PD-L1 Rechallenge', American Association for Cancer Research (AACR) (2023)
|
|||||||
Show 3 more others |
Preprint (3 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2024 |
Bond DR, Burnard SM, Uddipto K, Hunt KV, Harvey BM, Reinhardt LS, et al., 'Upregulated cholesterol biosynthesis facilitates the survival of methylation-retaining AML cells following decitabine treatment (2024)
|
|||||||
2023 |
Matthews B, Wong-Brown M, Liu D, Yee C, Dickson K-A, Schneider J, et al., 'Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer (2023)
|
|||||||
2023 |
Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, Tooney PA, 'ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines (2023)
|
Grants and Funding
Summary
Number of grants | 68 |
---|---|
Total funding | $16,873,504 |
Click on a grant title below to expand the full details for that specific grant.
20234 grants / $136,736
An Achilles’ heel of ovarian cancer: targeting ARID1A mutant tumours$73,690
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Nikola Bowden, Professor Deborah Marsh |
Scheme | Ideas Grants |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2025 |
GNo | G2300304 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
Development of ovarian cancer detection test$39,332
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Michelle Brown, Professor Nikola Bowden |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2026 |
GNo | G2301073 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
PRIME005: Phase II study of azacitidine and carboplatin priming for ipilimumab and nivolumab re-challenge in patients with advanced melanoma who are resistant to immunotherapy (Translational secondary$13,714
Funding body: Irene Lojszczyk
Funding body | Irene Lojszczyk |
---|---|
Project Team | Professor Nikola Bowden, Mr Andre Van Der Westhuizen |
Scheme | Research Project |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2024 |
GNo | G2301270 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Drug Repurposing in Treatment Resistant Ovarian Cancer$10,000
Funding body: Tour De Cure
Funding body | Tour De Cure |
---|---|
Project Team | Professor Nikola Bowden, Professor Nikola Bowden, Doctor Michelle Brown, Associate Professor Paul Tooney, Mr Bayley Matthews |
Scheme | PhD Support Scholarship |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2201031 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
20225 grants / $1,009,054
Sartorious Incucyte SX5 Live-Cell Analysis Instrument for high throughput screening of drugs for repurposing as chemotherapy in the treatment of cancer$400,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Doctor Michelle Brown, Professor Nikola Bowden, Karen Briscoe, Professor Doan Ngo, Dr Frank Reimann, Professor Aaron Sverdlov |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200706 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Histology Grant 2022$235,745
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2101355 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Cancer Institute NSW / NSW RHP- translational research and capacity building grant.$223,441
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Translational Cancer Research Capacity Building |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2026 |
GNo | G2300182 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Drug Repurposing for Ovarian Cancer$100,000
Funding body: Maitland Cancer Appeal Committee Incorporated
Funding body | Maitland Cancer Appeal Committee Incorporated |
---|---|
Project Team | Professor Nikola Bowden, Professor Alister Page, Doctor Michelle Brown |
Scheme | Research Funding |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200742 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Laboratory equipment to expand the cytotoxic facility at HMRI$49,868
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200121 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20214 grants / $6,648,914
NSW Regional Health Partners Cancer Translation Consortium$5,624,999
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Translational Cancer Research Capacity Building |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2026 |
GNo | G2100090 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
PRIME005: Phase II study of Azacitidine and Carboplatin priming for Ipilimumab and Nivolumab re-challenge in patients with advanced melanoma who are resistant to immunotherapy$881,430
Funding body: Bristol-Myers Squibb Australia Pty Ltd
Funding body | Bristol-Myers Squibb Australia Pty Ltd |
---|---|
Project Team | Professor Nikola Bowden, Professor Nikola Bowden, Professor Nikola Bowden, Dr Andre van der Westhuizen |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2025 |
GNo | G2001501 |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | Y |
Jill Emberson Pink meets Teal HMRI PhD Scholarship$112,989
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Mr Bayley Matthews |
Scheme | Jill Emberson Pink meets Teal HMRI PhD Scholarship |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2024 |
GNo | G2001129 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Glioblastoma Research Program – DNA Repair Laboratory equipment$29,496
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Paul Tooney, Professor Nikola Bowden |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100196 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20203 grants / $2,865,949
Australian Program for Drug Repurposing for Ovarian Cancer Treatment$2,736,499
Funding body: Department of Health and Aged Care
Funding body | Department of Health and Aged Care |
---|---|
Project Team | Professor Nikola Bowden, Professor Jennifer Martin, Doctor Michelle Brown, Associate Professor Deborah Marsh, Associate Professor Deborah Marsh, Caroline Ford, Dr David Thomas, Dr David Thomas, Emeritus Professor Richard Head, Ms Penny Reeves, Ms Gill Stannard |
Scheme | MRFF - EPCDR - Ovarian Cancer |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2025 |
GNo | G2000012 |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | Y |
Can we make brain cancer more susceptible to radiotherapy and chemotherapy by blocking its ability to repair DNA damage?$100,000
Funding body: Tour De Cure
Funding body | Tour De Cure |
---|---|
Project Team | Associate Professor Paul Tooney, Doctor Michael Fay, Professor Nikola Bowden |
Scheme | Pioneering Research Grant |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2021 |
GNo | G1901173 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
Testing of CSIRO technology to detect high grade serous ovarian cancer cells in blood samples$29,450
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Distinguished Emeritus Professor John Aitken, Doctor Michelle Brown |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | G2000097 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20196 grants / $665,356
Early phase high throughput studies of cannabinoids using new understandings of glioblastoma biology, radiobiology and pharmacology$190,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Jennifer Martin, Doctor Michael Fay, Doctor James Lynam, Doctor Catherine Lucas, Doctor Peter Galettis, Professor Nikola Bowden, Associate Professor Jenny Schneider, Associate Professor Paul Tooney, Doctor Ross Norris, Doctor Moira Graves |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2021 |
GNo | G1900511 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy$180,000
Funding body: Merck Group
Funding body | Merck Group |
---|---|
Project Team | Professor Nikola Bowden, Professor Nikola Bowden, Doctor Moira Graves, Mr Ricardo Vilain, Dr Andre van der Westhuizen, Dr Andre van der Westhuizen |
Scheme | Investigator Sponsor Trials |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2021 |
GNo | G1801426 |
Type Of Funding | C3400 – International For Profit |
Category | 3400 |
UON | Y |
Overcoming immunotherapy resistance in the treatment of patients with advanced melanoma$130,000
Funding body: Calvary Mater Newcastle
Funding body | Calvary Mater Newcastle |
---|---|
Project Team | Professor Nikola Bowden, Dr Andre van der Westhuizen |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2020 |
GNo | G1900721 |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | Y |
Can we target PSMA to effectively treat recurrent glioblastoma?$72,550
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Michael Fay, Associate Professor Paul Tooney, Professor Nikola Bowden, Doctor Moira Graves, Dr Thomas Robertson |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1901139 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Repurposing existing drugs to overcome ovarian cancer chemoresistance$67,806
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Michelle Brown, Professor Jennifer Martin, Emeritus Professor Richard Head |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1901179 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Repurposing drugs into effective cancer treatments$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Jennifer Martin, Professor Nikola Bowden, Emeritus Professor Richard Head |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2020 |
GNo | G1901341 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
20189 grants / $995,408
Hunter Cancer Biobank$725,684
Funding body: NSW Health Pathology - Pathology North
Funding body | NSW Health Pathology - Pathology North |
---|---|
Project Team | Professor Marjorie Walker, Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Professor Pradeep Tanwar, Associate Professor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Professor Nikola Bowden, Associate Professor Kelly Kiejda, Professor Simon Keely, Doctor Christopher Rowe |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2022 |
GNo | G1800704 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Repurposing traditional chemotherapy to prime advanced melanoma for immune therapy$100,000
Funding body: Maitland Cancer Appeal Committee Incorporated
Funding body | Maitland Cancer Appeal Committee Incorporated |
---|---|
Project Team | Professor Nikola Bowden, Doctor Moira Graves |
Scheme | Research Project |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1701600 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Selection of peptides targeting high grade serous ovarian cancer cell surface using random peptide phage display$57,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Distinguished Emeritus Professor John Aitken |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2020 |
GNo | G1801081 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Finding new treatment options for brain tumors with DNA repair inhibitors$30,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Moira Graves, Doctor Jennette Sakoff, Doctor Michael Fay, Associate Professor Paul Tooney, Professor Nikola Bowden |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | G1801321 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Do white blood cells from the bone marrow play a role in regrowth of glioblastoma and can blocking their movement into the brain improve treatment?$30,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Moira Graves, Professor Nikola Bowden, Doctor Michelle Brown |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2020 |
GNo | G1901577 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Standard doses of anti-PD-1 immunotherapy for metastatic melanoma may not be sufficient for all patients and may influence patient response to therapy$20,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Moira Graves, Dr Andre van der Westhuizen, Mr Ricardo Vilain, Doctor Peter Galettis |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801346 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Investigation of DNA repair and the epigenome in chemoresistant high grade serous ovarian cancer$18,253
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Michelle Brown |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800025 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Investigation of DNA repair and the epigenome in chemoresistant high grade serous ovarian cancer$14,471
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Michelle Brown |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800026 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Vanessa McGuigan HMRI Fellowship in Ovarian Cancer$0
Funding body: Hunter Medical Research Institute (HMRI)
Funding body | Hunter Medical Research Institute (HMRI) |
---|---|
Scheme | Mid-Career Fellowship |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2027 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
20173 grants / $933,500
HMRI Research Fellowship in Ovarian Cancer $864,500
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Research Funding |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2026 |
GNo | G1700972 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Repurposing traditional chemotherapy to prime advanced melanoma for immune therapy$44,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Dr Andre van der Westhuizen |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | G1701355 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Re-purposing PARP inhibitors to treat childhood leukaemias$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Professor Nikola Bowden, Doctor Lisa Lincz, Doctor Anoop Enjeti, Doctor Frank Alvaro |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | G1701561 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20161 grants / $55,000
Repurposing traditional chemotherapy to prime advanced melanoma for immune therapy.$55,000
Funding body: Ramaciotti Foundations
Funding body | Ramaciotti Foundations |
---|---|
Project Team | Professor Nikola Bowden, Dr Andre van der Westhuizen |
Scheme | Health Investment Grant |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | G1500637 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
201511 grants / $1,570,083
Investigation of the DNA repair protein XPC in melanoma treatment resistance.$600,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Career Development Fellowship |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2017 |
GNo | G1400706 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Expanding basic, clinical and functional genomic cancer research at Concord Campus$385,470
Funding body: Cancer Instititue NSW
Funding body | Cancer Instititue NSW |
---|---|
Project Team | Nico van Zandwijk |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$300,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Marjorie Walker, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Emeritus Professor John Forbes, Professor Xu Dong Zhang, Professor Pradeep Tanwar, Professor Nikola Bowden, Doctor Craig Gedye, Doctor James Lynam, Associate Professor Kelly Kiejda, Doctor Jennette Sakoff, Mr Loui Rassam, Dr Tara Roberts, Professor Soon Lee, Dr Betty Kan |
Scheme | Research Infrastructure Grants |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2018 |
GNo | G1500825 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$124,938
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Associate Professor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Professor Christopher Scarlett, Professor Pradeep Tanwar, Associate Professor Kathryn Skelding, Doctor Rick Thorne, Professor Nikola Bowden |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | G1500598 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Deep Learning of Complex Genomics Data for Effective Clinical Decisions.$60,000
Funding body: Cancer Instititue NSW
Funding body | Cancer Instititue NSW |
---|---|
Scheme | Big Data, Big Impact Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
Destroying kidney cells that evade current treatments$46,000
Funding body: Kidney Health Australia
Funding body | Kidney Health Australia |
---|---|
Project Team | Doctor Craig Gedye, Professor Nikola Bowden, Professor Rodney Scott |
Scheme | Medical Research Project Grants |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1401048 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$25,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Associate Professor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Professor Christopher Scarlett, Professor Pradeep Tanwar, Associate Professor Kathryn Skelding, Doctor Rick Thorne, Professor Nikola Bowden |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500953 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$16,675
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Craig Gedye, Professor Rodney Scott, Professor Nikola Bowden, Professor Simon Keely, Associate Professor Kathryn Skelding |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500730 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Tour de Cure Travel Grant - AACR Conference, USA, April 2016 - Chloe Warren$5,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1600221 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Travel Grant - AACR Conference, USA, April 2016 - Moira Graves$5,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1600222 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Society for Melanoma Research Congress, San Fransisco USA, 18-22 November 2015$2,000
Funding body: University of Newcastle - Faculty of Health and Medicine
Funding body | University of Newcastle - Faculty of Health and Medicine |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1501052 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20141 grants / $60,000
Generating Actionable Knowledge from Complex Genomic Data for Personalised Clinical Decisions.$60,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Daniel Catchpoole |
Scheme | Big data, Big Impact Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
20132 grants / $431,372
Development of a chemotherapy response/resistance test for ovarian cancer$231,590
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2013 |
Funding Finish | 2017 |
GNo | G1300897 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Investigation of the nucleotide excision repair pathway for melanoma biomarkers. $199,782
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2013 |
Funding Finish | 2016 |
GNo | G1200391 |
Type Of Funding | C2100 - Aust Commonwealth – Own Purpose |
Category | 2100 |
UON | Y |
20125 grants / $133,855
Research Equipment$54,355
Funding body: Hunter Melanoma Foundation
Funding body | Hunter Melanoma Foundation |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Research Equipment Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2013 |
GNo | G1200936 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Development of a diagnostic genetic test for childhood skin cancer disorders$40,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Professor Rodney Scott |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1200164 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Development of a diagnostic test for Xeroderma Pigmentosum , Cockayne’s Syndrome and Trichothiodystrophy$17,500
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1300524 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Emerging Research Leaders Program 2011$15,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Emerging Research Leaders Program |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1101040 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Rotary Club of Cardiff Melanoma Scholar Award$7,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2013 |
GNo | G1200831 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
20112 grants / $590,811
Priority Research Centre for Cancer$555,811
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Emeritus Professor John Forbes, Emeritus Professor Leonie Ashman, Professor Nikola Bowden, Professor Gordon Burns, Conjoint Professor Jim Denham, Professor Hubert Hondermarck, Doctor Lisa Lincz, Doctor Jennette Sakoff, Professor Peter Stanwell, Doctor Rick Thorne, Associate Professor Nikki Verrills |
Scheme | Priority Research Centre |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2016 |
GNo | G1101013 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Nucleotide excision repair gene expression in melanoma$35,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Katie Ashton, Doctor Stephen Braye, Professor Rodney Scott, Dr Ricardo Vilain |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1001057 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
20102 grants / $91,975
Altered nucleotide excision repair in melanoma in response to cisplatin and UV-light irradiation$90,000
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Priority-driven Collaborative Cancer Research Scheme |
Role | Lead |
Funding Start | 2010 |
Funding Finish | 2010 |
GNo | G0190317 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
101st American Association of Cancer Research Annual Meeting, Convention Centre, Washington DC, USA, 17 - 21st April 2010$1,975
Funding body: University of Newcastle - Faculty of Health and Medicine
Funding body | University of Newcastle - Faculty of Health and Medicine |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2010 |
Funding Finish | 2011 |
GNo | G1000132 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20093 grants / $518,921
Molecular mechanisms of UV-light induced skin malignancies$333,921
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Early Career Fellowships |
Role | Lead |
Funding Start | 2009 |
Funding Finish | 2014 |
GNo | G0189304 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
Genome wide SNP associated study of childhood acute lymphoblastic leukaemia$140,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Rodney Scott, Professor Nikola Bowden, Doctor Bente Talseth-Palmer |
Scheme | Paediatric Oncology Project Grant |
Role | Investigator |
Funding Start | 2009 |
Funding Finish | 2010 |
GNo | G0189790 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Gene expression profiling of Xeroderma pigmentosum$45,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Rodney Scott, Professor Nikola Bowden, Doctor Katie Ashton |
Scheme | Postdoctoral Fellowship |
Role | Investigator |
Funding Start | 2009 |
Funding Finish | 2010 |
GNo | G0900194 |
Type Of Funding | Donation - Aust Non Government |
Category | 3AFD |
UON | Y |
20083 grants / $121,730
Gene expression profiling of xeroderma pigmentosum$100,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Rodney Scott, Professor Nikola Bowden |
Scheme | Postdoctoral Fellowship |
Role | Investigator |
Funding Start | 2008 |
Funding Finish | 2008 |
GNo | G0188353 |
Type Of Funding | Donation - Aust Non Government |
Category | 3AFD |
UON | Y |
Genome wide SNP association study of childhood acute lymphoblastic leukaemia$20,000
Funding body: Hunter Children`s Research Foundation
Funding body | Hunter Children`s Research Foundation |
---|---|
Project Team | Professor Nikola Bowden, Professor Rodney Scott, Doctor Bente Talseth-Palmer |
Scheme | Paediatric Oncology Project Grant |
Role | Lead |
Funding Start | 2008 |
Funding Finish | 2008 |
GNo | G0188483 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Australian health & meidcal Research Congress, Brisbane Convention Centre, 16/11/2008 - 21/11/2008$1,730
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2008 |
Funding Finish | 2008 |
GNo | G0189663 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20073 grants / $33,000
Gene expression profiling of xeroderma pigmentosum$20,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Professor Rodney Scott |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0187261 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Identification of a predictive approach to assigning to undefined xeroderma pigmentosum patients to subgroups using gene expression profiling$10,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0187256 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Travel prize to attend: 4th Annual Illumina User Meeting (March '08) and American Association for Cancer Research (AACR) 99th Annual Meeting (April 12-16 '08)$3,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | PULSE Education Prize |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2007 |
GNo | G0187298 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
20061 grants / $11,840
Gene Expression Profiling of Xeroderma Pigmentosum$11,840
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Professor Nikola Bowden |
Scheme | Early Career Researcher Grant |
Role | Lead |
Funding Start | 2006 |
Funding Finish | 2006 |
GNo | G0186964 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2023 | PhD | Development of Ovarian Cancer Detection Test | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2021 | PhD | Evaluating the Impact of Obesity on Endometrial Cancer Patient’s Health Outcomes and Barriers to Preventative Strategies: A Mixed Method Approach | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2021 | PhD | Drug Repurposing for Treatment-Resistant Ovarian Cancer | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2020 | PhD | Investigating the Contribution of Tumour Cells to the Vasculature of Glioblastoma | PhD (Experimental Pharmacol), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2017 | PhD | Overcoming Immunotherapy Resistance in the Treatment of Patients with Advanced Melanoma | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2023 | PhD | Will DNA Repair Inhibitors Improve Survival of Patients with Brain Cancer? | PhD (Experimental Pharmacol), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2022 | PhD | Single Cell Epigenomics in Myeloid Malignancies | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2017 | PhD | Examining the Expression of Nucleotide Excision Repair Genes in Melanoma Tumours | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2017 | PhD | The Role of Nucleotide Excision Repair in Melanoma Development and Platinum Chemotherapy Resistance | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2017 | PhD | Expression of the Uncharacterised Isoform, BCL2ß, in Melanoma | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2016 | PhD | The Role of Short Tandem Repeats in Genetic Susceptibility to Breast and Endometrial Cancers | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2015 | Masters | Nucleotide Excision Repair of UVA-Induced DNA Damage: Regulation in Sunlight-Induced Melanoma | M Philosophy (Medical Genetic), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2014 | PhD | The Contribution of Genetic Susceptibility to Breast Cancer | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2013 | PhD | The Complex Genetics of Multiple Sclerosis | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Research Collaborations
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
Country | Count of Publications | |
---|---|---|
Australia | 102 | |
United Kingdom | 4 | |
Canada | 2 | |
Sweden | 2 | |
France | 1 | |
More... |
News
News • 12 Sep 2022
Researchers discover potential new melanoma treatment, giving hope to patients
HMRI and University of Newcastle researchers have discovered that treating patients who have late-stage treatment resistant melanoma with a combination of two existing drugs significantly increases their survival times.
News • 9 May 2017
Cancer fellowship for UON researcher
Honouring the profoundly tragic loss of their cherished daughter Vanessa, winemaking legends Brian and Fay McGuigan – together with the University of Newcastle – have jointly funded an unprecedented 10-year Hunter Medical Research Institute Fellowship dedicated to ovarian cancer research.
News • 9 Mar 2017
A voice for gender equity
In an exciting step forward toward gender equity, Dr Nikola Bowden has been appointed to the NHMRC Women in Health Science working committee.
News • 21 Oct 2015
UON researcher Dr Nikola Bowden wins Young Tall Poppy Science Award
Outstanding University of Newcastle (UON) researcher Dr Nikola Bowden has been named one of Australia's 'Tall Poppies' in science at the prestigious NSW Young Tall Poppy Science Awards at the Sydney Powerhouse Museum.
News • 25 Feb 2015
DNA protein targeted in ovarian cancer chemo test
University of Newcastle researcher Dr Nikola Bowden is investigating a DNA repair protein that is implicated in ovarian cancer tumours becoming resistant to chemotherapy, with hopes of eventually developing a prognostic test and more tailored treatments.
Professor Nikola Bowden
Position
Research Fellow
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Focus area
Medical Genetics
Contact Details
nikola.bowden@newcastle.edu.au | |
Phone | (02) 40420277 |
Fax | 02 40420031 |
Link |
Office
Room | HMRI Level 3 West |
---|---|
Building | HMRI |
Location | HMRI , |